Safety and efficacy of ipilimumab in patients with advanced cutaneous melanoma :A real world experience

Trial Profile

Safety and efficacy of ipilimumab in patients with advanced cutaneous melanoma :A real world experience

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 New trial record
    • 02 Nov 2016 Results (n=811; data cut-off March 20, 2016) presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 11 Oct 2016 Results (n=891; data cut-off April 14th 2016) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top